Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans

Drug Metabolism and Disposition

Volumn 41, Issue 4, 2013, Pages 683-688

  Sugimoto, Hiroshi ^a   Hirabayashi, Hideki ^a   Amano, Nobuyuki ^a   Moriwaki, Toshiya ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYCLOSPORIN A; KETOCONAZOLE; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; N NORLOPERAMIDE; QUINIDINE; SAQUINAVIR; TARIQUIDAR; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ANIMALS; BLOOD-BRAIN BARRIER; DRUG INTERACTIONS; HUMANS; LLC-PK1 CELLS; LOPERAMIDE; P-GLYCOPROTEIN; QUINOLINES; SWINE; VERAPAMIL;

RATTUS;

EID: 84875851139     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049577     Document Type: Article

References (34)

1. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, and Urbatsch IL, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science 323:1718-1722.
2. 11C]verapamil. Ann Nucl Med 24:83-87.
3. Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, Jäger W, Böhmdorfer M, Wadsak W, Mitterhauser M, and Bankstahl JP, et al. (2012) Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther 91:227-233.
4. Brunton L, Lazo J, and Parker K (2005) Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ed. 11th. McGraw-Hill Professional, New York.
5. Chan LM, Lowes S, and Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25-51.
6. Eyal S, Hsiao P, and Unadkat JD (2009) Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123:80-104.
7. Eyal S, Ke B, Muzi M, Link JM, Mankoff DA, Collier AC, and Unadkat JD (2010) Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther 87:579-585.
8. Fullerton T, Bednar M, Raava P, Legg J, Hoelscher D, Eckols D, and Gibbs M (2005) Characterization of P-glycoprotein inhibition at the blood brain barrier by ketoconazole and quinidine using the central pharmacodynamics of loperamide as an indicator of brain distribution. Clin Pharmacol Ther 77:31-33.
9. Grandvuinet AS, Vestergaard HT, Rapin N, and Steffansen B (2012) Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions. J Pharm Pharmacol 64:1523-1548.
10. Jamis-Dow CA, Pearl ML, Watkins PB, Blake DS, Klecker RW, and Collins JM (1997) Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole. Am J Clin Oncol 20:592-599.
11. Kannan P, Brimacombe KR, Zoghbi SS, Liow JS, Morse C, Taku AK, Pike VW, Halldin C, Innis RB, and Gottesman MM, et al. (2010) N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos 38:917-922.
12. Kharasch ED, Hoffer C, and Whittington D (2004) The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 57:600-610.
13. Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, Herscovitch P, Pike VW, and Innis RB (2010) P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med 51:559-566.
14. Kurnik D, Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJ, and Muszkat M (2008) Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. Anesthesiology 109:1092-1099.
15. Lee CA, Cook JA, Reyner EL, and Smith DA (2010) P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 6: 603-619.
16. Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, Windhorst AD, Franssen EJ, and Lammertsma AA (2007) Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab 27: 424-433.
17. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, and Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624-632.
18. Mikus G, Schmidt L, Burhenne J, Ding R, Riedel KD, Tayrouz Y, Weiss J, and Haefeli WE (2004) Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. Clin Pharmacokinet 43:1015-1024.
19. Passchier J, Comley R, Salinas C, Rabiner E, Gunn R, Cunningham V, Wilson A, Houle S, Gee A, and Laruelle M (2008) The role of P-glycoprotein on blood brain barrier permeability of [11C]Loperamide in humans. Neuroimage 41:T192.
20. Sadeque AJ, Wandel C, He H, Shah S, and Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
21. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, and Unadkat JD (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503-514.
22. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995) Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
23. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, and Bevan P (2000) Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6:4186-4191.
24. Sugimoto H, Hirabayashi H, Kimura Y, Furuta A, Amano N, and Moriwaki T (2011a) Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across bloodbrain barrier in rats. Drug Metab Dispos 39:8-14.
25. Sugimoto H, Matsumoto S, Tachibana M, Niwa S, Hirabayashi H, Amano N, and Moriwaki T (2011b) Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci 100: 4013-4023.
26. Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Långström B, Knudsen GM, and Hammarlund-Udenaes M (2009) Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37:635-643.
27. Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, Katoh M, Yokoi T, and Asahi S (2006) Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res 23:1460-1472.
28. Tsuji A (2002) Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet 17:253-274.
29. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, Moritani S, Tsuruo T, and Yamashita J (1992) P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 51:1427-1437.
30. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, and Terasaki T (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 117:333-345.
31. Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, Kletter K, Löscher W, Müller M, and Zeitlinger M, et al. (2009) A pilot study to assess the efficacy of tariquidar to inhibit Pglycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med 50:1954-1961.
32. Wei HM, Weiss HR, Sinha AK, and Chi OZ (1993) Effects of nitric oxide synthase inhibition on regional cerebral blood flow and vascular resistance in conscious and isoflurane-anesthetized rats. Anesth Analg 77:880-885.
33. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885.
34. Zoghbi SS, Liow JS, Yasuno F, Hong J, Tuan E, Lazarova N, Gladding RL, Pike VW, and Innis RB (2008) 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 49:649-656.